A Phase 1 interventional study of JP-1366 20mg tablet and JP-1366 20mg tablet in Healthy, sponsored by Onconic Therapeutics Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-26.
Sponsored by Onconic Therapeutics Inc. · Phase 1, Interventional, and Treatment
To Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral single dose of JP-1366 tablet in Healthy volunteers
Onconic Therapeutics Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
T → Washout period(7-14days) → R
Drug: JP-1366 20mg tablet
R → Washout period(7-14days) → T
Drug: JP-1366 20mg tablet
T : JP-1366 20mg tablet after the meal
R : JP-1366 20mg tablet under fasting condition
Cmax of JP-1366
Time frame: Pre-dose(0 hour) and up to 34 hours in each period
AUClast of JP-1366
Time frame: Pre-dose(0 hour) and up to 34 hours in each period
Gastric pH
Time frame: Pre-dose(0 hour) up to 24 hours after Investigational product administration
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Onconic Therapeutics Inc.